Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pioglitazone
Drug ID BADD_D01777
Description Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence.[L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ).[A19757] PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.[A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.[L11461]
Indications and Usage Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[L11416] It is also available in combination with [metformin],[L11419] [glimepiride],[L11422] or [alogliptin][L11425] for the same indication.
Marketing Status approved; investigational
ATC Code A10BG03
DrugBank ID DB01132
KEGG ID D08378
MeSH ID D000077205
PubChem ID 4829
TTD Drug ID D03OFF
NDC Product Code 0093-7271; 50090-4586; 53002-2757; 61919-781; 64764-151; 68071-5210; 68382-308; 71335-1333; 71335-1385; 43547-428; 71610-495; 72189-105; 0781-5421; 0781-5422; 0904-7090; 50090-4556; 50090-6412; 53002-2755; 68071-5245; 68788-7514; 70518-2129; 71335-1759; 71335-1298; 16714-647; 33342-054; 57237-220; 57237-221; 68382-306; 68788-7989; 70518-2609; 70771-1021; 71335-1659; 0781-5420; 11532-0012; 16714-645; 0093-7272; 64764-301; 64764-451; 70771-1023; 71335-1343; 33342-055; 43547-427; 57237-219; 68071-2886; 68071-4964; 0904-7096; 16729-020; 50090-4605; 70518-2431; 70771-1022; 72189-293; 16714-646; 60687-391; 68788-7511; 71335-1137; 16729-021; 0093-7273; 43547-426; 68071-2264; 68382-307; 11532-0011; 11532-0013; 16729-022; 33342-056; 53002-2756
UNII X4OV71U42S
Synonyms Pioglitazone | 5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione | U 72107A | U72,107A | U-72107A | U72107A | AD 4833 | AD-4833 | AD4833 | Pioglitazone Hydrochloride | Actos
Chemical Information
Molecular Formula C19H20N2O3S
CAS Registry Number 111025-46-8
SMILES CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000172%Not Available
Diabetic retinal oedema14.07.01.001; 05.07.01.001; 06.04.06.001--Not Available
Diabetic retinopathy14.07.01.002; 06.10.02.002; 05.07.01.002; 24.03.07.0040.000129%Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.0020.000343%
Ear disorder04.03.01.001--Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Fracture15.08.02.001; 12.04.02.001--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.000129%
Glycosuria20.02.01.005--
Glycosylated haemoglobin decreased13.02.02.012--Not Available
Haematocrit decreased13.01.05.001--Not Available
Haematuria24.07.01.047; 20.02.01.006; 21.10.01.0180.001288%
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatitis09.01.07.004--Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages